4.0%) did not differ by sex (Table 2). final site, Tnf Miami Beach, began testing on May 21, 2020. Healthcare workers and first responders self-seeking SARS-CoV-2 testing were designated for antibody testing and completed a laboratory collection form onsite for the point-of-care test. All testing was performed on Rofecoxib (Vioxx) whole blood specimens (obtained by venipuncture) using the Cellex Inc. qSARS-CoV-2 IgG/IgM Rapid Test. Seropositivity was assessed by univariate analysis and by Rofecoxib (Vioxx) logistic regression including the covariates age, sex, race/ethnicity, and testing location. Results and Discussion: As of June 3, 2020, of 5,779 healthcare workers and first responders tested, 4.1% were seropositive (range 2.6C8.2%). SARS-COV-2 antibody assessments had higher odds of being positive for persons testing at the Miami Hard Rock Stadium (aOR 2.24 [95% C.I. 1.48C3.39]), persons of Haitian/Creole ethnicity (aOR 3.28 [95% C.I. 1.23C8.72]), Hispanic/Latino(a) ethnicity (aOR 2.17 [95% C.I. 1.50C3.13], and Black non-Hispanic persons (aOR 1.63 [95% C.I. 1.08C2.46]). SARS-COV-2 antibody prevalence among first responders and healthcare workers in five sites Rofecoxib (Vioxx) in Florida varied by race and ethnicity and by testing location. Introduction | Rofecoxib (Vioxx) The SARS-CoV-2 virus responsible for severe respiratory infection associated with coronavirus infectious disease 2019 (COVID-19) was first identified and confirmed in Florida on March 1, 2020. Between March 1, 2020 and June 4, 2020, 60,183 persons in Florida were diagnosed with COVID-19 and 2,607 had COVID-19-associated mortality.1 Large-scale testing is one of the major pillars in Floridas response efforts to detect and contain the transmission of COVID-19. As of June 4, 2020, over 1,107,000 persons in Florida had been tested at public health, commercial and hospital laboratories; results indicated a state positivity rate of 5.3 percent by RT-PCR and 3.6% positivity for initially tested persons with SARS-CoV-2, as some persons were retested to determine if virus was still present. Following the first persons diagnosed with SARS-CoV-2 in Florida, State Surgeon General Scott Rivkees declared a Public Health Emergency on March 1st. This was closely followed by a State of Emergency declared by Governor Ron DeSantis who issued statewide stay at home orders with guidance to practice social distancing and other prevention measures in accordance with national guidelines.2C4 As of June 4, 2020, all 67 of Floridas counties had confirmed cases, with Miami-Dade County having the highest test positivity rate (10%) and 32 percent of total cases statewide.1 Other top metropolitan counties with substantial disease burden included Broward (6% positivity, 12% of total cases), Palm Beach (8% positivity, 11% of total cases), Hillsborough (4% positivity, 4% of total cases), Orange (3% positivity, 4% of total cases), and Duval counties (3% positivity, 3% of total cases). As the incidence of COVID-19 increased across Florida, demand for SARS-CoV-2 virus testing also grew exponentially, leading to the establishment of state-wide drive-thru testing operations via partnerships between the Department of Health, Division of Emergency Management, and the National Guard. These testing strategies improved and provided direct and easy access to diagnostic testing to reach the Rofecoxib (Vioxx) broader population. Drive-through testing formats had previously been touted as a safe and effective method for large volume testing initiatives that directly detect the pathogen during pandemic situations and have the benefit of reducing the number of infectious persons entering and contaminating healthcare establishments as well as promoting social distancing.5,6 Approximately two months after the initial cases were identified in Florida, point-of-care (POC) SARS-CoV-2 antibody testing was offered to healthcare workers and first responders at five drive-through COVID-19 testing locations to assess the seroprevalence of antibodies against the SARS-CoV-2 circulating in the Florida population. Antibody testing has been used in many diseases previously to track and understand seroprevalence of disease including Zika virus.